GleamWall
中文EN

BETRF BetterLife Pharma Inc. IFRS

Pharmaceutical Preparations · OTC · SEC CIK 1464165 · Reporting currency CAD · Fiscal year ends 01/31

Financial factors as of 2025-01-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY-21.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,280.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3,372.6%
Debt / equity—
Current ratio—
Interest coverage-30.29x

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-545.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2020Q12019-04-30 · CAD2019Q32018-10-31 · USD2019Q22018-07-31 · USD2018Q12018-04-30 · USD2018Q32017-10-31 · USD2018Q3*2017-10-30 · USD2018Q22017-07-31 · USD2018Q12017-04-30 · USD
Income statement
Revenue————————
R&D expense59,487$65,029$86,781$85,293————
SG&A expense506,786$432,112$427,753$749,415$50,480$50,480$75,641$53,289
Operating income-1.66M-$1.41M-$1.18M-$1.45M-$184,658-$184,658-$248,755-$285,518
Interest expense239,728$134,851$96,962$67,665$7,331$7,327$8,365$8,789
Net income-1.87M-$3.38M-$1.41M-$1.62M$530,726$530,730-$5,556-$319,812
EPS (basic)-0.02-0.04-0.02-0.020.01—0.000.00
EPS (diluted)-0.02-0.04-0.02-0.020.01—0.000.00
Weighted avg. shares (diluted)99.54M89.63M85.36M86.21M81.60M—75.74M75.65M
Banking
Net interest income—$2,923——————
Balance sheet
Cash & equivalents45,414$406,901$474,491$1.51M$250,386$250,386$9,943$46,698
Inventory—$6,795——————
Current assets193,847$556,024$676,865$1.66M$295,912—$33,138$63,502
PP&E, netmay include right-of-use assets (IFRS)—$3,404$3,641$3,879————
Intangibles8.26M$6.52M$6.71M$6.95M$239,247———
Total assets9.55M$7.08M$7.59M$8.81M$535,159—$36,038$66,402
Current liabilities5.32M$3.65M——$150,025—$1.32M$1.80M
Total liabilities6.18M$3.65M$4.29M$4.22M$352,222—$1.32M$1.80M
Shareholders' equity3.37M$3.43M$3.30M$4.59M$182,937—-$1.28M-$1.73M
Shares outstanding105.94M95.83M88.50M88.06M79.60M—75.85M75.65M
Cash flow statement
Operating cash flow-567,811-$705,895-$982,799-$1.87M—-$70,689-$38,540-$64,982
Investing cash flow—-$326,666$0-$333,333————
Financing cash flow526,000$998,394-$84,774$3.67M—$307,125$22,500$3,000
Stock-based compensation5,896——34,898CAD———$417

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.